BBOT
92 employees
Biotech/Pharma
Public · $461.0M
Open positions (6)
Company details
Team Size92
IndustryBiotech/Pharma
Funding
Total raised
$461.0M
Last stage
Public
Investors
Deerfield Management
Total raised
$461.0M
Last stage
Public
Investors
Eli Wallace
PhD; led BBOT as CEO from its 2024 spinout from BridgeBio Pharma; previously Chief Scientific Officer at Peloton Therapeutics; stepped down as CEO in April 2026.
Pedro J. Beltran
PhD; co-founded and served as Chief Scientific Officer at BBOT; appointed CEO in April 2026 following Eli Wallace's departure.
LinkedInNeil Kumar
PhD; Founder & CEO of BridgeBio Pharma; instrumental in spinning out BBOT in 2024; appointed Executive Chairman of BBOT in April 2026.
No applications, no recruiter spam. Just the intro.
A few questions to make sure this role is the right shape for you. Two minutes.
I write the intro, send it to the founder, and handle the back-and-forth.
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.